Barclays’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-227,600
| Closed | -$19.3M | – | 6739 |
|
|
2019
Q4 | $19.3M | Buy |
227,600
+220,900
| +3,297% | +$14.7M | 0.01% | 973 |
|
|
2019
Q3 | $335K | Buy |
6,700
+4,600
| +219% | +$183K | ﹤0.01% | 4577 |
|
|
2019
Q2 | $77K | Buy |
2,100
+400
| +24% | +$13.1K | ﹤0.01% | 5872 |
|
|
2019
Q1 | $48K | Sell |
1,700
-39,800
| -96% | -$938K | ﹤0.01% | 5916 |
|
|
2018
Q4 | $794K | Buy |
41,500
+39,500
| +1,975% | +$919K | ﹤0.01% | 3350 |
|
|
2018
Q3 | $60K | Sell |
2,000
-1,400
| -41% | -$52.7K | ﹤0.01% | 5971 |
|
|
2018
Q2 | $125K | Buy |
3,400
+1,400
| +70% | +$45.5K | ﹤0.01% | 5090 |
|
|
2018
Q1 | $66K | Buy |
2,000
+1,000
| +100% | +$31.2K | ﹤0.01% | 5676 |
|
|
2017
Q4 | $27K | Sell |
1,000
-36,600
| -97% | -$1.13M | ﹤0.01% | 6145 |
|
|
2017
Q3 | $1.39M | Buy |
37,600
+10,600
| +39% | +$391K | ﹤0.01% | 2691 |
|
|
2017
Q2 | $1.03M | Sell |
27,000
-5,300
| -16% | -$236K | ﹤0.01% | 2864 |
|
|
2017
Q1 | $1.58M | Buy |
+32,300
| New | +$1.47M | ﹤0.01% | 2311 |
|
|
2016
Q4 | – | Sell |
-130,400
| Closed | -$4.92M | – | 6970 |
|
|
2016
Q3 | $4.92M | Buy |
130,400
+128,500
| +6,763% | +$4.84M | 0.01% | 1308 |
|
|
2016
Q2 | $64K | Buy |
+1,900
| New | +$67K | ﹤0.01% | 4707 |
|
|
2015
Q3 | – | Sell |
-1,000
| Closed | -$28K | – | 7178 |
|
|
2015
Q2 | $28K | Buy |
+1,000
| New | +$27.9K | ﹤0.01% | 5492 |
|
|
2013
Q4 | – | Sell |
-15,800
| Closed | -$521K | – | 7772 |
|
|
2013
Q3 | $521K | Buy |
+15,800
| New | +$503K | ﹤0.01% | 4066 |
|
Other funds holding MDCO
Barclays's MDCO Position: Q1 2020 in Review
Barclays sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 325,106 shares — an estimated $27.6M sold.
Barclays first reported a position in MDCO in Q2 2013 and held it in 27 quarters. The position peaked at $27.6M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- Barclays reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- Barclays sold 325,106 Medicines Co shares in Q1 2020, an estimated $27.6M.
- Barclays first reported a position in Medicines Co in Q2 2013 and held it in 27 quarters.
- Barclays's Medicines Co position peaked at $27.6M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.